Form 8-K - Current report:
SEC Accession No. 0001171843-25-005383
Filing Date
2025-08-13
Accepted
2025-08-13 17:00:34
Documents
14
Period of Report
2025-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_081325.htm   iXBRL 8-K 15457
2 PRESS RELEASE exh_991.htm EX-99.1 59809
  Complete submission text file 0001171843-25-005383.txt   279739

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
16 EXTRACTED XBRL INSTANCE DOCUMENT f8k_081325_htm.xml XML 3153
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 251212646
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)